Royalty Pharma Plc (RPRX)vsRevolution Medicines Inc (RVMD)

RPRX

Royalty Pharma Plc

NASDAQ

$49.47

-1.24%

HEALTHCARE · Cap: $29.33B

RVMD

Revolution Medicines Inc

NASDAQ

$139.48

-3.22%

HEALTHCARE · Cap: $29.65B

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Royalty Pharma Plc generates 320411% more annual revenue ($2.38B vs $742,000). RPRX leads profitability with a 32.4% profit margin vs 0.0%. RPRX earns a higher WallStSmart Score of 57/100 (C).

RPRX

Buy

out of 100

Grade: C

Growth: 4.7Profit: 8.0Value: 4.0Quality: 3.5

Piotroski: 2/9Altman Z: 1.15

RVMD

Avoid

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 7.3

Piotroski: 2/9Altman Z: 3.27

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

RPRXOvervalued (-11.3%)

Margin of Safety

-11.3%

Fair Value

$39.76

Current Price

$49.47

$9.71 premium

UndervaluedFair: $39.76Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RPRX2 strengths · Avg: 10.0/10

Profit MarginProfitability

32.4%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability

57.7%10/10

Strong operational efficiency at 57.7%

RVMD1 strengths · Avg: 10.0/10

Altman Z-ScoreHealth

3.2710/10

Safe zone — low bankruptcy risk

Areas to Watch

RPRX4 concerns · Avg: 3.5/10

P/E RatioValuation

27.8x4/10

Moderate valuation

Revenue GrowthGrowth

4.8%4/10

4.8% revenue growth

Debt/EquityHealth

1.383/10

Elevated debt levels

Piotroski F-ScoreQuality

2/93/10

Weak financial health signals

RVMD4 concerns · Avg: 3.5/10

Price/BookValuation

16.8x4/10

Trading at 16.8x book value

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Profit MarginProfitability

0.0%3/10

0.0% margin — thin

Operating MarginProfitability

0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : RPRX

The strongest argument for RPRX centers on Profit Margin, Operating Margin. Profitability is solid with margins at 32.4% and operating margin at 57.7%.

Bull Case : RVMD

The strongest argument for RVMD centers on Altman Z-Score.

Bear Case : RPRX

The primary concerns for RPRX are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

RVMD carries more volatility with a beta of 1.01 — expect wider price swings.

RPRX is growing revenue faster at 4.8% — sustainability is the question.

RPRX generates stronger free cash flow (827M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RPRX scores higher overall (57/100 vs 24/100), backed by strong 32.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Royalty Pharma Plc

HEALTHCARE · BIOTECHNOLOGY · USA

Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.

Visit Website →

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Compare with Other BIOTECHNOLOGY Stocks

RPRX vs VRTX RPRX vs REGN RPRX vs ARGX RPRX vs ALNY RPRX vs ONC RVMD vs VRTX RVMD vs REGN RVMD vs ARGX RVMD vs ALNY RVMD vs ONC

Want to dig deeper into these stocks?

Full RPRX Analysis →Full RVMD Analysis →